Biosimilars and reference biological medicines in the treatment of rheumatoid arthritis: a multicenter cross-sectional study in Catalonia, Spain
Clinical Rheumatology · 2025
DOI: 10.1007/s10067-025-07568-9 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Clinical Rheumatology, 2025. Verfasst von Joan Mas Marin und 15 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacy and Pharmaceutical Care Unit, Department of Pharmacy and Pharmaceutical Technology, and Physical Chemistry, Faculty of Pharmacy and…. Hauptthemen laut MEDLINE: Antirheumatic Agents, Arthritis, Rheumatoid, Biological Products, Biosimilar Pharmaceuticals. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universitat de Barcelona.
Abstract (Originalsprache)
Objective
The objective of this study is to compare the effectiveness of reference biologic medicines used in the treatment of rheumatoid arthritis (RA) specifically adalimumab, etanercept, and infliximab, with corresponding biosimilar medicines, based on an exploratory analysis of clinical data obtained in patients treated with these medicines in five hospitals in the region of Catalonia, Spain.
Methods
There is a consultation of the database of the Registry of Patients and Treatments of the Catalan Health Service: extraction of data from adult patients diagnosed with moderate and severe active RA and with active prescription of at least one biological drug (reference or biosimilar) or JAK inhibitor. To compare the effectiveness of each reference biologic with its biosimilar, differences in mean DAS28-ESR values before and after treatment were assessed for adalimumab and its biosimilar, etanercept and its biosimilar, and infliximab and its biosimilar.
Results
The study consisted of 643 patients. The most dispensed medicines were anti-TNFs, with 303 patients on treatment. Thirty-six percent of all patients were using biosimilars. No statistically significant differences were observed in any of the three comparisons between the reference biologic medicine and its biosimilar. These findings suggest that biosimilars have comparable effectiveness to reference biologics in reducing DAS28-ESR; in addition, they can provide substantial savings to public health systems.
Conclusions
A significant number of patients diagnosed with moderate to severe active RA were treated with biological medicines and receiving the available biosimilar treatments. Future research should be conducted to confirm comparable effectiveness found to their reference biologic medicines in this exploratory analysis. Key Points • Biosimilar use: 36% of rheumatoid arthritis (RA) patients in Catalonia are treated with biosimilars, exceeding the 12% recommendation. This reflects growing acceptance of these alternatives. • Comparative effectiveness: Biosimilars of adalimumab, etanercept, and infliximab showed comparable therapeutic benefit to their reference biologics in reducing disease activity in active rheumatoid arthritis. • Real-world data: The study provides real-world data from five hospitals, making biosimilar medicines a viable choice for rheumatologists in routine rheumatoid arthritis management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Pharmacy and Pharmaceutical Care Unit, Department of Pharmacy and Pharmaceutical Technology, and Physical Chemistry, Faculty of Pharmacy and Food Sciences, University of Barcelona, Av. Joan XXIII, 27-31, 08028,…
- Pharmacy Service, Hospital General de Granollers, Av. Francesc Ribas s/n, 08402, Granollers, Barcelona, Spain.
- Pharmacy Service, Fundació Hospital de l'Esperit Sant, Av. Mossèn Pons i Rabadà s/n, 08923, Santa Coloma de Gramenet, Barcelona, Spain.
- Pharmacy Service, Hospital Universitari Sagrat Cor, C/ Viladomat, 288, 08029, Barcelona, Spain.
- Pharmacy Service, Hospital de la Santa Creu i Sant Pau, C/ Sant Antoni Mª Claret 167, 08025, Barcelona, Spain.
- Pharmacy Service, Hospital Universitari Germans Trias i Pujol, Carretera de Canyet s/n, 08916, Badalona, Barcelona, Spain.
Förderung
- Universitat de Barcelona
Zitieren
APA
Mas Marin, J., Molina-Olano, M., Sola, N. R., Miserachs-Aranda, N., Montoliu Alcón, P., De Pourcq, J. T., Quiñones Ribas, C., Borràs Trias, L., Fernández-Cañabate, E., González-Valdivieso, J., Figueiredo-Escribá, C., Delgado-Hernández, R., Braza, A. J., Lastra, C. F., Mariño, E. L., & Modamio, P. (2025). Biosimilars and reference biological medicines in the treatment of rheumatoid arthritis: a multicenter cross-sectional study in Catalonia, Spain. Clinical Rheumatology. https://doi.org/10.1007/s10067-025-07568-9
Vancouver
Mas Marin J, Molina-Olano M, Sola NR, Miserachs-Aranda N, Montoliu Alcón P, De Pourcq JT, et al. Biosimilars and reference biological medicines in the treatment of rheumatoid arthritis: a multicenter cross-sectional study in Catalonia, Spain. Clinical Rheumatology. 2025. doi:10.1007/s10067-025-07568-9
BibTeX
@article{MasMarin2025,
author = {Mas Marin, Joan and Molina-Olano, Marina and Sola, Nuria Rudi and Miserachs-Aranda, Núria and Montoliu Alcón, Paula and De Pourcq, Jan T and Quiñones Ribas, Carles and Borràs Trias, Laura and Fernández-Cañabate, Eva and González-Valdivieso, Juan and Figueiredo-Escribá, Carlos and Delgado-Hernández, René and Braza, Antonio J and Lastra, Cecilia F and Mariño, Eduardo L and Modamio, Pilar},
title = {Biosimilars and reference biological medicines in the treatment of rheumatoid arthritis: a multicenter cross-sectional study in Catalonia, Spain},
journal = {Clinical Rheumatology},
year = {2025},
doi = {10.1007/s10067-025-07568-9}
}
EUVIMED